Targets for inhibition of HIV replication: entry, enzyme action, release and maturation (Q37979697)

26 August 2017

title

Targets for inhibition of HIV replication: entry, enzyme action, release and maturation (English)

1 reference

26 August 2017

2

Hauke Walter

1 reference

26 August 2017

Saleta Sierra-Aragón

1

1 reference

26 August 2017

language of work or name

1 reference

24 January 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

55

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

84-97

1 reference

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

26 August 2017

cites work

1 reference

Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug

21 January 2018

1 reference

Active human immunodeficiency virus protease is required for viral infectivity

21 January 2018

1 reference

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

21 January 2018

1 reference

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients

21 January 2018

1 reference

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

21 January 2018

1 reference

Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection

21 January 2018

1 reference

HIV 10 years later-where do we stand now?

21 January 2018

1 reference

The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection

21 January 2018

1 reference

Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins

21 January 2018

1 reference

HIV-1 gp41 fusion intermediate: a target for HIV therapeutics

21 January 2018

1 reference

HIV infection is blocked in vitro by recombinant soluble CD4.

21 January 2018

1 reference

Inhibition of HIV-1 Env-Mediated Cell-Cell Fusion by Lectins, Peptide T-20, and Neutralizing Antibodies

21 January 2018

1 reference

Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors

21 January 2018

1 reference

High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates

21 January 2018

1 reference

Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug.

21 January 2018

1 reference

Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.

21 January 2018

1 reference

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

21 January 2018

1 reference

Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins

21 January 2018

1 reference

Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155.

21 January 2018

1 reference

Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis

21 January 2018

1 reference

Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope

21 January 2018

1 reference

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

21 January 2018

1 reference

Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection

21 January 2018

1 reference

Maraviroc for previously treated patients with R5 HIV-1 infection

21 January 2018

1 reference

Are the proposed env mutations actually associated with resistance to maraviroc?

21 January 2018

1 reference

Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)

21 January 2018

1 reference

TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans

21 January 2018

1 reference

Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652.

21 January 2018

1 reference

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140

21 January 2018

1 reference

Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro

21 January 2018

1 reference

Full-length and truncated neurokinin-1 receptor expression and function during monocyte/macrophage differentiation

21 January 2018

1 reference

Enfuvirtide: a review of its use in the management of HIV infection

21 January 2018

1 reference

Complete nucleotide sequence of the AIDS virus, HTLV-III

21 January 2018

1 reference

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

21 January 2018

1 reference

Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus

21 January 2018

1 reference

Revisiting HIV-1 uncoating

21 January 2018

1 reference

Uncoating of HIV-1 requires cellular activation.

21 January 2018

1 reference

Reconstitution of retroviral fusion and uncoating in a cell-free system

21 January 2018

1 reference

HIV-1 matrix protein: a mysterious regulator of the viral life cycle

21 January 2018

1 reference

Visualization of the intracellular behavior of HIV in living cells

21 January 2018

1 reference

Establishment of a functional human immunodeficiency virus type 1 (HIV-1) reverse transcription complex involves the cytoskeleton

21 January 2018

1 reference

Direct correlation between genome dimerization and recombination efficiency of HIV-1.

21 January 2018

1 reference

Molecular basis of fidelity of DNA synthesis and nucleotide specificity of retroviral reverse transcriptases

21 January 2018

1 reference

Molecular basis of human immunodeficiency virus drug resistance: an update.

21 January 2018

1 reference

International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance

21 January 2018

1 reference

Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir

21 January 2018

1 reference

Mutations E44D and V118I in the reverse transcriptase of HIV-1 play distinct mechanistic roles in dual resistance to AZT and 3TC.

21 January 2018

1 reference

Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance

21 January 2018

1 reference

A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase

21 January 2018

1 reference

Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism

21 January 2018

1 reference

Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates

21 January 2018

1 reference

Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein

21 January 2018

1 reference

Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase

21 January 2018

1 reference

TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments

21 January 2018

1 reference

Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance

21 January 2018

1 reference

Viral protein R regulates nuclear import of the HIV-1 pre-integration complex

21 January 2018

1 reference

Characterization of HIV-1 vpr nuclear import: analysis of signals and pathways

21 January 2018

1 reference

Nucleocytoplasmic shuttling by human immunodeficiency virus type 1 Vpr.

21 January 2018

1 reference

The Vpr protein from HIV-1: distinct roles along the viral life cycle

21 January 2018

1 reference

Nuclear translocation as a novel target for anti-HIV drugs

21 January 2018

1 reference

HIV-1 integrase inhibitors: 2007-2008 update

21 January 2018

1 reference

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

21 January 2018

1 reference

Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles

21 January 2018

1 reference

Evolution of raltegravir resistance during therapy.

21 January 2018

1 reference

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro

21 January 2018

1 reference

Raltegravir treatment response in an HIV-2 infected patient: a case report

21 January 2018

1 reference

Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen

21 January 2018

1 reference

Novel HIV-1 integrase inhibitors derived from quinolone antibiotics

21 January 2018

1 reference

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)

21 January 2018

1 reference

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors

21 January 2018

1 reference

Basics of the virology of HIV-1 and its replication

21 January 2018

1 reference

Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy

21 January 2018

1 reference

Requirement for an intact T-cell actin and tubulin cytoskeleton for efficient assembly and spread of human immunodeficiency virus type 1.

21 January 2018

1 reference

Structural organization of authentic, mature HIV-1 virions and cores

21 January 2018

1 reference

Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism

21 January 2018

1 reference

Kinetic analysis of the role of intersubunit interactions in human immunodeficiency virus type 1 capsid protein assembly in vitro

21 January 2018

1 reference

Organization of immature human immunodeficiency virus type 1

21 January 2018

1 reference

HIV-1 capsid protein forms spherical (immature-like) and tubular (mature-like) particles in vitro: structure switching by pH-induced conformational changes

21 January 2018

1 reference

Implications of antiretroviral resistance on viral fitness

21 January 2018

1 reference

Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag

21 January 2018

1 reference

Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1

21 January 2018

1 reference

Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.

21 January 2018

1 reference

High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates

21 January 2018

1 reference

Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results

21 January 2018

1 reference

New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.

21 January 2018

1 reference

In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000331995

1 reference

26 August 2017

1 reference